1.Erratum: Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue.
Seok Joong YUN ; Pildu JEONG ; Ho Won KANG ; Helen Ki SHINN ; Ye Hwan KIM ; Chunri YAN ; Young Ki CHOI ; Dongho KIM ; Dong Hee RYU ; Yun Sok HA ; Tae Hwan KIM ; Tae Gyun KWON ; Jung Min KIM ; Sang Heon SUH ; Seon Kyu KIM ; Seon Young KIM ; Sang Tae KIM ; Won Tae KIM ; Ok Jun LEE ; Sung Kwon MOON ; Nam Hyung KIM ; Isaac Yi KIM ; Jayoung KIM ; Hee Jae CHA ; Yung Hyun CHOI ; Eun Jong CHA ; Wun Jae KIM
International Neurourology Journal 2016;20(4):374-374
In this article, a part of fund and grant supports was omitted unintentionally.
2.Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue.
Seok Joong YUN ; Pildu JEONG ; Ho Won KANG ; Helen Ki SHINN ; Ye Hwan KIM ; Chunri YAN ; Young Ki CHOI ; Dongho KIM ; Dong Hee RYU ; Yun Sok HA ; Tae Hwan KIM ; Tae Gyun KWON ; Jung Min KIM ; Sang Heon SUH ; Seon Kyu KIM ; Seon Young KIM ; Sang Tae KIM ; Won Tae KIM ; Ok Jun LEE ; Sung Kwon MOON ; Nam Hyung KIM ; Isaac Yi KIM ; Jayoung KIM ; Hee Jae CHA ; Yung Hyun CHOI ; Eun Jong CHA ; Wun Jae KIM
International Neurourology Journal 2016;20(2):122-130
PURPOSE: Previously, we reported the presence of virus-encoded microRNAs (miRNAs) in the urine of prostate cancer (CaP) patients. In this study, we investigated the expression of two herpes virus-encoded miRNAs in prostate tissue. METHODS: A total of 175 tissue samples from noncancerous benign prostatic hyperplasia (BPH), 248 tissue samples from patients with CaP and BPH, and 50 samples from noncancerous surrounding tissues from these same patients were analyzed for the expression of two herpes virus-encoded miRNAs by real-time polymerase chain reaction (PCR) and immunocytochemistry using nanoparticles as molecular beacons. RESULTS: Real-time reverse transcription-PCR results revealed significantly higher expression of hsv1-miR-H18 and hsv2-miRH9- 5p in surrounding noncancerous and CaP tissues than that in BPH tissue (each comparison, P<0.001). Of note, these miRNA were expressed equivalently in the CaP tissues and surrounding noncancerous tissues. Moreover, immunocytochemistry clearly demonstrated a significant enrichment of both hsv1-miR-H18 and hsv2-miR-H9 beacon-labeled cells in CaP and surrounding noncancerous tissue compared to that in BPH tissue (each comparison, P<0.05 for hsv1-miR-H18 and hsv2- miR-H9). CONCLUSIONS: These results suggest that increased expression of hsv1-miR-H18 and hsv2-miR-H95p might be associated with tumorigenesis in the prostate. Further studies will be required to elucidate the role of these miRNAs with respect to CaP and herpes viral infections.
Carcinogenesis
;
Herpesviridae
;
Humans
;
Hyperplasia*
;
Immunohistochemistry
;
MicroRNAs
;
Nanoparticles
;
Prostate*
;
Prostatic Hyperplasia
;
Prostatic Neoplasms
;
Real-Time Polymerase Chain Reaction
3.Predictors of Successful Smoking Cessation after Inpatient Intervention for Stroke Patients.
Eugene HA ; Jun Yong JO ; Ah Leum AHN ; Eun Jung OH ; Jae Kyung CHOI ; Dong Yung CHO ; Hyuk Jung KWEON
Korean Journal of Family Medicine 2016;37(2):85-90
BACKGROUND: Smoking is a well-known risk factor of cancer, chronic disease, and cerebrovascular disease. Hospital admission is a good time to quit smoking but patients have little opportunity to take part in an intensive smoking cessation intervention. The purpose of this study was to identify the factors of successful smoking cessation among stroke patients who undergo an intensive cessation intervention during the hospitalization period. METHODS: Thirty-nine male smokers who were admitted with stroke were enrolled in the study. They participated in a smoking cessation intervention during hospitalization. Smoking status was followed up by telephone 3 months later. Nicotine dependence, sociodemographic factors, and other clinical characteristics were assessed. RESULTS: After 3 months post-intervention, the number of patients who stopped smoking was 27 (69.2%). In addition, there was no significant difference in nicotine dependence, sociodemographic factors, and clinical characteristics. Only the stages of readiness for smoking cessation were a significant predictor (odds ratio, 18.86; 95% confidence interval, 1.59-223.22). CONCLUSION: This study shows that a patient's willingness to quit is the most significant predictor of stopping smoking after Inpatient cessation Intervention for stroke Patients.
Chronic Disease
;
Counseling
;
Hospitalization
;
Humans
;
Inpatients*
;
Male
;
Risk Factors
;
Smoke*
;
Smoking Cessation*
;
Smoking*
;
Stroke*
;
Telephone
;
Tobacco Use Disorder
4.Occurrence and characterization of oseltamivir-resistant influenza virus in children between 2007-2008 and 2008-2009 seasons.
Seoung Geun KIM ; Yoon Ha HWANG ; Yung Hae SHIN ; Sung Won KIM ; Woo Sik JUNG ; Sung Mi KIM ; Jae Min OH ; Na Young LEE ; Mun Ju KIM ; Kyung Soon CHO ; Yeon Gyeong PARK ; Sang Kee MIN ; Chang Kyu LEE ; Jun Sub KIM ; Chun KANG ; Joo Yeon LEE ; Man Kyu HUH ; Chang Hoon KIM
Korean Journal of Pediatrics 2013;56(4):165-175
PURPOSE: There was a global increase in the prevalence of oseltamivir-resistant influenza viruses during the 2007-2008 influenza season. This study was conducted to investigate the occurrence and characteristics of oseltamivir-resistant influenza viruses during the 2007-2008 and 2008-2009 influenza seasons among patients who were treated with oseltamivir (group A) and those that did not receive oseltamivir (group B). METHODS: A prospective study was conducted on 321 pediatric patients who were hospitalized because of influenza during the 2007-2008 and 2008-2009 influenza seasons. Drug resistance tests were conducted on influenza viruses isolated from 91 patients. RESULTS: There was no significant difference between the clinical characteristics of groups A and B during both seasons. Influenza A/H1N1, isolated from both groups A and B during the 2007-2008 and 2008-2009 periods, was not resistant to zanamivir. However, phenotypic analysis of the virus revealed a high oseltamivir IC50 range and that H275Y substitution of the neuraminidase (NA) gene and partial variation of the hemagglutinin (HA) gene did not affect its antigenicity to the HA vaccine even though group A had a shorter hospitalization duration and fewer lower respiratory tract complications than group B. In addition, there was no significant difference in the clinical manifestations between oseltamivir-susceptible and oseltamivir-resistant strains of influenza A/H1N1. CONCLUSION: Establishment of guidelines to efficiently treat influenza with oseltamivir, a commonly used drug for treating influenza in Korean pediatric patients, and a treatment strategy with a new therapeutic agent is required.
Child
;
Drug Resistance
;
Hemagglutinins
;
Hospitalization
;
Humans
;
Influenza, Human
;
Inhibitory Concentration 50
;
Neuraminidase
;
Orthomyxoviridae
;
Oseltamivir
;
Prevalence
;
Prospective Studies
;
Respiratory System
;
Seasons
;
Viruses
;
Zanamivir
5.Two Cases of an Implantation of a Permanent Pacemaker Using a Transaxillary Incision.
Jae Hoon CHOI ; Jun KIM ; Tae Ik PARK ; Hyung Ha JANG ; Tae Kun LEE ; Sang Kwon LEE ; Han Cheol LEE ; June Hong KIM ; Kook Jin CHUN ; Taek Jong HONG ; Yung Woo SHIN
Korean Circulation Journal 2008;38(9):500-504
In surgeries that require the implantation of a pacemaker, the endocardial pacemaker leads are introduced into the cardiac chambers through subclavian or axillary venous catheterization or cephalic vein cutdown. The drawback of this type of surgery is scarring of the pectoral area, which can be a serious cosmetic problem especially for young women. In this study, we report on 2 cases where a permanent pacemaker in two young women with symptomatic bradycardia was implanted using a transaxillary incision. Both patients successfully recovered with no complications and were asymptomatic for more than 17 months after the procedure. Therefore, we found that implantation of a pacemaker via transaxillary incision provided excellent cosmetic results and should be considered in young women that require this type of surgery.
Axilla
;
Bradycardia
;
Catheterization
;
Catheters
;
Cicatrix
;
Cosmetics
;
Female
;
Humans
;
Venous Cutdown
6.Prognosis According to the Timing of Percutaneous Coronary Intervention in an Acute Non-ST Segment Elevation Myocardial Infarction.
Sung Gyu AN ; Tae Ik PARK ; Sang Hyun LEE ; Hyung Ha JANG ; Dong Won LEE ; Jae Kyung HA ; Han Cheol LEE ; Jun KIM ; June Hong KIM ; Kook Jin CHUN ; Taek Jong HONG ; Yung Woo SHIN
Korean Circulation Journal 2008;38(1):23-28
BACKGROUND AND OBJECTIVES: An early invasive strategy with coronary angiography and revascularization is currently the recommended treatment for patients at high risk with an acute non-ST-segment elevation myocardial infarction (NSTEMI). In this early invasive strategy, percutaneous coronary intervention (PCI) is generally recommended within 48 hours, but there is little data on earlier intervention in intermediate risk patients. SUBJECTS AND METHODS: We studied retrospectively the past medical records of 118 patients at intermediate risk that were admitted at Pusan National University Hospital and were stratified by the time interval from chest pain onset to PCI (Group I: <24 hr; Group II: 24-48 h; Group III: >48 h). Clinical outcomes were evaluated in terms of in-hospital and 12 months follow-up of a major adverse cardiac event (MACE). RESULTS: Baseline characteristics were not different statistically among the three groups, except for the use of tirofiban. There were no in-hospital deaths or myocardial infarctions (MI) in Group I and Group II patients, but there were three cases of in-hospital deaths in Group III patients. The incidence of a 12-month MACE was 0% in Group I patients, 6.7% (one revascularization) in Group II patients and 17.1% (3 deaths, 3 MIs, 7 revascularizations) in Group III patients (p=0.043). CONCLUSION: In acute NSTEMI, the incidence of a 12-month MACE was lower in the intermediate risk group when PCI was performed in the early period. Early PCI could be recommended in acute NSTEMI on the basis of the status of individual patients.
Angioplasty, Balloon, Coronary
;
Chest Pain
;
Coronary Angiography
;
Early Intervention (Education)
;
Follow-Up Studies
;
Humans
;
Incidence
;
Medical Records
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Prognosis
;
Retrospective Studies
;
Tyrosine
7.Metabolic Syndrome and Risk of In-Stent Restenosis: Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
Jae Kyung HA ; Dong Cheul HAN ; Ki Won HWANG ; Dong Won LEE ; Yung Kwon YUN ; Han Cheol LEE ; Jun KIM ; June Hong KIM ; Kook Jin CHUN ; Taek Jong HONG ; Yung Woo SHIN
Korean Circulation Journal 2007;37(11):567-573
BACKGROUND AND OBJECTIVES: Patients with metabolic syndrome (MS) have an increased risk of cardiovascular events. However, only limited studies are available on the effect of MS on restenosis and on the clinical outcome of patients undergoing percutaneous coronary intervention (PCI). The aim of this study is to assess the role of MS in the development of restenosis, and risk of a 6-month major adverse cardiac event (MACE) and a 12-month MACE, as well as the difference of outcome between the use of bare metal stents (BMSs) and the use of drug eluting stents (DESs). SUBJECTS AND METHODS: This is a one center, retrospective study. The study population comprised 151 patients undergoing percutaneous coronary intervention (PCI) with BMSs and 200 patients undergoing PCI with DESs. The study population was classified into two groups of patients with MS and patients without MS. RESULTS: The baseline clinical characteristics were similar in the two groups (with or without MS) except for hypertension, diabetes, body mass index, triglyceride level and high-density lipoprotein level. The frequency of in-stent restenosis of the patients that were implanted with BMSs or DESs was not different between two groups, based on a 6 month follow-up quantitative coronary angiographic analysis (BMSs: 30% vs 22.2%, p= 0.352; DES: 3.3% vs 2.2%, p=0.76; for patients with and without MS, respectively). The percent of patients with a 6-month MACE for patients implanted with BMSs was not statistically different for patients with or without MS (30% vs 22.2%, p=0.352) but the percent of patients with a 12-month MACE showed a statistically significant higher level for the MS group (38.6% vs 23.5%, p=0.044). The percent of patients with a 6-month MACE for patients implanted with DESs was also not statistically different between two groups (5.8% vs 1.7%, p= 0.123). CONCLUSION: Patients with MS undergoing BMSs or DESs implantation do not show higher levels of in-stent restenosis and levels of a 6-month MACE. The number of 12-month MACEs of patients implanted with BMSs is statistically higher, but the number of 6-month MACEs of patients implanted with DESs is not different for the MS group. We conclude that MS is not risk factor of in-stent restenosis in PCI but MS may influence the long-term clinical outcome in patients undergoing PCI.
Body Mass Index
;
Coronary Restenosis
;
Drug-Eluting Stents
;
Follow-Up Studies
;
Humans
;
Hypertension
;
Lipoproteins
;
Percutaneous Coronary Intervention*
;
Retrospective Studies
;
Risk Factors
;
Stents
;
Triglycerides
8.Comparison of the Clinical and Angiographic Outcomes of Compromised Side Branches (Stent Jail) after Percutaneous Coronary Intervention between Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents.
Dong Won LEE ; Jae Kyung HA ; Sung Gyu AN ; Jae Hoon CHOI ; Tae Kun LEE ; Han Cheol LEE ; Jun KIM ; June Hong KIM ; Kook Jin CHUN ; Taek Jong HONG ; Yung Woo SHIN
Korean Circulation Journal 2007;37(12):630-634
BACKGROUND AND OBJECTIVES: Drug-eluting stents (DES) have been used worldwide for conducting safe and effective percutaneous coronary intervention (PCI) for treating coronary artery disease. However, the DES might cause a higher frequency of an acute side branch occlusion or stent jails near the target lesion after PCI than that with using bare metal stents (BMS). This may be due to the eluted drug or the thick stent struts. We evaluated the clinical and angiographic outcomes of compromised side branches (stent jail) after PCI and the frequency of side branch occlusion or stent jails between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). SUBJECTS AND METHODS: We analyzed the clinical results and angiographic findings of 47 patients who were treated with a SES and 45 patients who were treated with a PES. We only analyzed the left anterior descending artery (LAD) and its side branches that were more than one millimeter in diameter. Side branch occlusion was defined as the development of total occlusion or a reduction of the thrombolysis in myocardial infarction (TIMI) flow more than grade 1 after stenting. The peak cardiac enzyme levels were measured. We evaluated the clinical outcomes in the hospital and at the 6 month follow up. RESULTS: There were no significant differences of the baseline clinical demographics between the SES and the PES groups. The total length and diameter of the implanted stents were 42.85+/-15.3 mm vs. 41.68+/-13.3 mm (p=0.93) and 3.09+/-0.3 mm vs. 3.1+/-0.2 mm (p=0.69) in the SES group and PES group, respectively. On average, the number of side branches of the LAD were 2.00+/-0.9 vs. 2.13+/-0.8 and on angiography after stenting, side branch occlusion and reduction of the TIMI developed in 8.51% vs. 13.33% (p=0.46) and 17% vs. 15% (p=0.88) of the SES group and PES group, respectively. The laboratory data showed that the peak creatine kinase-MB (CK-MB) and troponin-I levels were 13.5+/-31 U/L vs. 15.6+/-33 U/L (p=0.77) and 6.3+/-15 ng/mL vs. 5.42+/-9 ng/mL (p=0.77), respectively. There were no clinical in-hospital events for either group. There were no statistically significant differences in major adverse cardiac events (MACEs) at the 6-month follow up (4.3% vs. 8.9%, respectively). CONCLUSION: The clinical and angiographic outcomes of compromised side branches (stent jail) after PCI and the frequency of side branch occlusion or stent jails between SES and PES were similar.
Angiography
;
Angioplasty, Balloon, Coronary
;
Arteries
;
Coronary Artery Disease
;
Coronary Occlusion
;
Creatine
;
Demography
;
Drug-Eluting Stents
;
Follow-Up Studies
;
Humans
;
Myocardial Infarction
;
Percutaneous Coronary Intervention*
;
Stents*
;
Troponin I
9.Minimally Invasive Lumbar Microdiscectomy using Tubular Retractor: A Preliminary Report.
Yung PARK ; Joong Won HA ; Hyun Cheol OH ; Ju Hyung YOO ; Yun Tae LEE ; Doo Hyung LEE ; Chul Jun CHOI
The Journal of the Korean Orthopaedic Association 2005;40(6):679-685
PURPOSE: To evaluate the early clinical results of lumbar microdiscectomy using minimally invasive tubular retractor (METRx-MD system, Medtronic Sofamor Danek, Memphis, TN), and to validate the merits of minimally invasive spinal surgery. MATERIALS AND METHODS: From April, 2003 to April 2004 we retrospectively studied a consecutive series of 45 patients who underwent lumbar microdiscectomy using minimally invasive tubular retractor. In all cases, minimally invasive approach using the tubular retractor were performed with a 2 cm sized paramedian incision. The following data were collected: clinical outcomes, operative time, intraoperative blood loss, need for blood replacement, time needed before ambulation, length of hospital stay, and complications. The clinical outcomes were assessed by the modified MacNab criteria. RESULTS: Minimally invasive tubular microdiscectomy was performed in 45 patients over a 12-month period with an average follow-up of approximately 8 months. The clinical outcomes assessed by MacNab criteria were excellent in 33 patients (73%), good in 10 patients (22%). The average operative time was 63 minutes (range, 35 to 95 minutes). The average blood loss was 62 mL (range, 50 to 110 mL). None of the patients needed blood replacement. With the exception of 2 patients, all patients could walk at the day of surgery. The average hospital stay was 2.3 days. None of the patients had dural tear, wound problem, or other complications. CONCLUSION: Lumbar microdiscectomy using tubular retractor can offer a useful modality for the treatment of lumbar herniated disc with the merits of minimally invasive spinal surgery. Further long-term, randomized, prospective investigations are needed to fully evaluate the impact of this technique.
Follow-Up Studies
;
Humans
;
Intervertebral Disc Displacement
;
Length of Stay
;
Operative Time
;
Wounds and Injuries
10.Biochemical Analysis of Serum and Pericardial Fluid in Patients with Hemorrhagic Pericardial Effusion.
Jae Kyung HA ; Taek Jong HONG ; Kook Jin CHUN ; Dong Won LEE ; Jeong Su KIM ; Jun Hyok OH ; Sung Gook SONG ; Tae Kun LEE ; June Hong KIM ; Yung Woo SHIN
Korean Circulation Journal 2003;33(3):227-232
BACKGROUND AND OBJECTIVES: Since echocardiography became a routine diagnostic tool, pericardial effusion has become a common clinical finding. The major causes of hemorrhagic pericardial effusion are malignancy and tuberculosis. However, it was unknown to the use of biochemical analysis of pericardial fluid and serum, for differentiation of malignancy from tuberculosis. To evaluate this, we investigated the biochemical analysis of pericardial fluid and serum in relation to the causes of pericardial tamponade. SUBJECTS AND METHODS: 46 patients who were admitted to Pusan National University Hospital from January 1, 1995, to April 30, 2002, and underwent both a pericardiocentesis and a pericardiostomy for the relif of cardiac tamponade, were included in this study. the pericardial fluid was routinely analyzed for the following: gross appearance, cell count, glucose, total protein(P), lactate dehydrogenase(LDH), cytology, gram stain, cultures for bacteria and mycobacterium, pericardial fluid to serum ratios of total protein and lactate dehydrogenase,(p/s TP, p/s LDH, respectively). RESULTS: f the 46 patients who underwent both pericardiocentesis and pericardiostomy, for the relief of cardiac tamponade, 33 patients(71.7%) had hemorrhagic pericardial effusion. The common causes of hemorrhagic pericardial effusion were malignancy(51.5%) and tuberculosis(33.3%) but, those of nonhemorrhagic pericardial effusion were idiopathic (38.5%). Cell counts were higher in hemorrhagic than nonhemorrhagic group(p=.029). Serum LDH(sLDH) was higher in malignant than tuberculous group(p=.001) but, serum total protein(sTP) was higher in tuberculous group(p=.004). Compared malignant group with tuberculosis group in patients with hemorrhagic pericardial effusion, p/s ratio of LDH and sTP were higher in tuberculous group (p=.029, p=.017), but sLDH was higher in malignant group(p=0.002). CONCLUSION: It is difficult to differentiate tuberculosis from malignancy only on the basis of the biochemical analysis of pericardial fluid in hemorrhagic pericardial effusion. However, the analysis of both pericardial fluid and serum may make it possible to evaluate the cause of pericardial effusion.
Bacteria
;
Blood Chemical Analysis
;
Busan
;
Cardiac Tamponade
;
Cell Count
;
Echocardiography
;
Glucose
;
Humans
;
Lactic Acid
;
Mycobacterium
;
Pericardial Effusion*
;
Pericardial Window Techniques
;
Pericardiocentesis
;
Tuberculosis

Result Analysis
Print
Save
E-mail